KRISTINA UNSELD: Open Payments
NPI 1245071257 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$925 in 60 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $339 · 2025 $925
Food & beverage: $925
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $294 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $214 |
| Otsuka America Pharmaceutical, Inc. | 11 | $155 |
| Neurocrine BioSciences, Inc. | 3 | $52 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 2 | $29 |
| JAZZ PHARMACEUTICALS INC. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
Products named: VRAYLAR, CAPLYTA, REXULTI, INGREZZA, Auvelity, Qelbree, COBENFY, INVEGA SUSTENNA.
Industry payments across NE — which companies pay providers there.
